The ideal of this thesis is to benefit patients that use lithium carbonate, through two studies: (1) comparison of the relative bioavailability/bioequivalence of two distinct lithium formulations; and (2) investigation of lithium use in children and adolescents. In order to analyze the bioequivalence, healthy volunteers (N=24), of both genders, were submitted to treatments of two lithium carbonate formulations (300 mg): test-Neurolithium and reference-Carbolitium. After a single dose administration of each formulation, plasma samples were collected to quantify lithium, using atomic absorption spectrophotometry. The method was developed specially to this study and it showed 0,07mg/L quantification limit. The geometric media and the 90% confiance interval test/reference was 104,77 (98,60-111,33%) to Cmax and 101,99 (96,81-107,44%) to ASClast. Based on FDA and ANVISA parameters, we concluded that Neurolithium is bioequivalent to Carbolitium. This thesis yearned for favoring patients that need lithium prescription through scientific evidences that assure the commercialization of a qualified formulation and make possible the register of a generic medication with low cost. Since information regarding the safety and effectiveness of lithium in children under 12 years of age is not available, its use in such patients is not recommended at this time. Therefore, the second study has investigated the use of lithium in pediatric patients, subdivided in two groups: under and over 12 years old. Patients that received lithium carbonate prescription inside the "Hospital de Clínicas" of Unicamp, in Campinas-SP, between 2000 January and 2006 December, were identified. Only clinical register of patients (N=77) under 21 years old, were selected and revised retroactively. We have noticed fewer doses administrations in patients under 12 years old. Seric levels and side effects indexes were not different between both groups. Patients under 12 years old showed reason for lithium prescription (aggressiveness) and indexes effectiveness per patient (71%) different from patients over 12 years old (humor oscillation; 83%). Since indexes effectiveness of both groups were in accordance with those found in literature and there was no difference in side effects number per patient, we concluded that the use of lithium in patients under 12 years old is feasible. Therefore, this thesis gives information regarding the use of lithium, which has grown without sufficient evidences supporting the effectiveness e safety in this pediatric population.